Horizon2020 CARAMBA CAR-T interview series

From T-cell collection to CAR T-cell infusion Myeloma Patients Europe (MPE) has conducted four written interviews on CAR-T manufacturing to better understand various myeloma CAR-T therapies’ manufacturing processes and challenges. Four stakeholders have answered our questions, including two pharmaceutical companies, each with a myeloma CAR-T product approved in the European Union, and two academic teams which have developed myeloma CAR-T products currently under clinical investigation.       Interview of Janssen Pharmaceuticals on their CAR T-cell manufacturing process…

Sign up for the MPE webinar on EHA myeloma and AL amyloidosis highlights 

Myeloma Patients Europe (MPE) will host a webinar to summarise the most important myeloma and AL amyloidosis updates presented at the congress on 6 July 2023, from 17:00 – 18:00 CET, given by Prof. Dr. Mohamad Mohty, Professor and Head of the Hematology and cellular therapy department at the Saint-Antoine Hospital and Sorbonne University (Paris, France).   If you would like to attend, click here and register now!   The European Hematology Association (EHA) 2023 hybrid congress took place from…

EHA 2023 highlights in myeloma and AL amyloidosis

The European Hematology Association’s (EHA) annual congress, one of the most important haematology congresses here in Europe, is being held in Frankfurt, Germany from 8 June to 15 June 2023 in a hybrid format. Myeloma Patients Europe (MPE) attended EHA 2023 in person and interviewed relevant myeloma and AL amyloidosis specialists to provide an overview of the key highlights in both diseases presented during this meeting. Watch below the main results of the following clinical…